Clinical trials: Ticagrelor
Carotid Artery Stenosis
Ticagrelor Versus Clopidogrel in Carotid Artery Stenting
Patients with symptomatic or asymptomatic carotid stenosis in whom carotid artery stenting is planned are randomised between antiplatelet therapy with ticagrelor plus aspirin or clopidogrel plus aspirin and examined with brain…
- Trial name
- PRECISE-MRI (NCT02677545)
- Testing
- Ticagrelor, Clopidogrel, Aspirin
- Where
- 15 sites in Belgium, Germany and 4 more
- Volunteers
- 210 people
- Sponsor
- University Hospital, Basel, Switzerland
Acute Coronary Syndromes
Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry
The primary objective of the UPSTREAM Registry is to address the data gap regarding the course of NSTEMI (Non-ST-Elevation Myocardial Infarction)between ED (Emergency Department) arrival and diagnostic angiography in detail, by…
- Trial name
- NCT02271022
- Testing
- Non-Interventional Study
- Where
- 55 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome
Ticagrelor Versus Clopidogrel in Myocardial Salvage in Patients With STEMI Undergoing Primary PCI
Therefore, in this study, we try to evaluate the impact of clopidogrel loading dose 300mg vs. ticagrelor 180 mg on myocardial injury as measured by contrast-enhanced magnetic resonance imaging (CE-MRI) in STEMI patients…
- Trial name
- NCT02792712
- Testing
- Ticagrelor, Clopidogrel
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Myocardial Ischemia, Coronary Artery Disease
Peripheral Endothelial Function Assessment of Patients on Ticagrelor vs. Clopidogrel Who Have Undergone PCI
Usage of antiplatelet agents and cardiac procedures such as coronary angioplasty has dramatically improved the morbidity and mortality associated with coronary artery disease.
- Conditions
- Myocardial Ischemia, Coronary Artery Disease, Endothelial Dysfunction
- Trial name
- NCT02469740
- Testing
- Ticagrelor, Clopidogrel
- Where
- Ireland
- Volunteers
- 61 people
- Sponsor
- University Hospital of Limerick
Antiplatelet Drug, Acute Coronary Syndrome
1-month DAPT Plus 5-month Ticagrelor Monotherapy Versus 12-month DAPT in Patients With Drug-coated Balloon
Drug-Coated Balloon (DCB) angioplasty is similar to plain old balloon angioplasty procedurally, but there is an anti-proliferative medication paclitaxel coated to the balloon.
- Conditions
- Antiplatelet Drug, Acute Coronary Syndrome, Angioplasty, Balloon
- Trial name
- CAGEFREEII (NCT04971356)
- Testing
- Aspirin 100mg for 1-month (immediately after PCI), Ticagrelor 90mg for 6-month (immediately after PCI), Aspirin 100mg for 6-month (6-month post PCI)
- Where
- China
- Volunteers
- 1,948 people
- Sponsor
- Xijing Hospital
Healthy
Dose Adaptation to Offset the Interaction Between Ticagrelor and Ritonavir by Population-based PK Modeling
Ticagrelor is a new generation antiplatelet agent with higher efficacy as compared to clopidogrel and prasugrel in treatment of patients with moderate and high ischemic risks.
- Trial name
- NCT02435563
- Testing
- ticagrelor 180 mg administrated alone, Ticagrelor adjusted dose + ritonavir 100mg
- Where
- Switzerland
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University Hospital, Geneva
Community Acquired Pneumonia, Severe
Ticagrelor in Severe Community Acquired Pneumonia
The purpose of this study is to determine if the drug ticagrelor will be an effective treatment for patients with severe community acquired pneumonia.
- Trial name
- TCAP (NCT01998399)
- Testing
- Ticagrelor
- Where
- 26 sites in United States
- Volunteers
- 25 people
- Sponsor
- Gordon Bernard
Platelet Aggregation, Adenosine
Platelet Aggregation in Patients With Coronary Artery Disease and Kidney Dysfunction Taking Clopidogrel or Ticagrelor
About 35% of patients hospitalized with Acute Coronary Syndromes (ACS) have some degree of renal dysfunction. Chronic kidney disease (CKD) is not only associated to worse prognosis in ACS patients, but leads also to an increased…
- Conditions
- Platelet Aggregation, Adenosine, Coronary Artery Disease, Kidney Dysfunction
- Trial name
- NCT03039205
- Testing
- Clopidogrel, Ticagrelor
- Where
- Brazil
- Volunteers
- 90 people
- Sponsor
- University of Sao Paulo
Saphenous Vein Graft Disease
Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis
Saphenous vein graft disease remains an unresolved medical problem. Many vein grafts occlude in the first year after bypass surgery, leading to adverse cardiovascular outcomes, including recurrent angina, myocardial infarction…
- Trial name
- TARGET (NCT02053909)
- Testing
- Aspirin, Ticagrelor
- Where
- 2 sites in United States, Canada
- Volunteers
- 250 people
- Sponsor
- Boca Raton Regional Hospital
Acute Ischaemic Stroke, Transient Ischaemic Attack
[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]
The primary objective of the study is to compare the effect of 90-day treatment with ticagrelor (180 mg [two 90 mg tablets] loading dose on Day 1 followed by 90 mg twice daily maintenance dose for the remainder of the study) vs…
- Trial name
- SOCRATES (NCT01994720)
- Testing
- ticagrelor, Acetylsalicylic acid (ASA)
- Where
- 521 sites in United States, Argentina and 31 more
- Volunteers
- 13,307 people
- Sponsor
- AstraZeneca
ST Elevation Myocardial Infarction
Safety of Ticagrelor Monotherapy After Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction and the Effect on Intramyocardial Haemorrhage
The main goal of this clinical trial is to assess whether direct omission of aspirin after Percutaneous Coronary Intervention (PCI) with the continuation of ticagrelor monotherapy for 12 months versus 12 months ticagrelor plus…
- Trial name
- STOP-IMH (NCT05986968)
- Testing
- Ticagrelor, Aspirin
- Where
- 5 sites in Netherlands
- Volunteers
- 200 people
- Sponsor
- Radboud University Medical Center
Aortic Valve Stenosis
Safety Profile Evaluation of TICagrelor Alone Compared to a Combination of Lysine Acetylsalicylate-Clopidogrel in the Context of Transcatheter Aortic Valve Implantation (TAVI)
Transcatheter Aortic Valve Implantation (TAVI) is now the method of choice to treat aortic stenosis in old and frail patients. Antiplatelet therapy must be associated for the procedure and during few weeks after implantation in…
- Trial name
- TICTAVI (NCT02817789)
- Testing
- Ticagrelor alone, Combination lysine acetylsalicylate - clopidogrel
- Where
- 5 sites in France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Bordeaux
Cardiac Surgery
Ticagrelor Hemoadsorption Using Cytosorb® for Reduction of Bleeding During Cardiac Surgery
Cardiac surgery is at high risk of intraoperative bleeding. Inhibitors of the P2Y12 platelet receptor, such as ticagrelor, are recommended in patients with acute coronary stroke (ACS) to reduce the incidence of major…
- Trial name
- TICAdSORB (NCT07822620)
- Testing
- Device: Cytosorb hemoadsorption
- Where
- France
- Volunteers
- 232 people
- Sponsor
- University Hospital, Rouen
Sickle Cell Disease
Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease.
The purpose of this study is to compare the effect of ticagrelor vs placebo for the reduction of Vaso-Occlusive crises in paediatric patients with Sickle Cell Disease
- Trial name
- HESTIA5 (NCT04293172)
- Testing
- Brilinta
- Sponsor
- AstraZeneca
Atrial Fibrillation, Percutaneous Coronary Intervention
Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)
The main objective of this study is to compare a Dual Antithrombotic Therapy (DAT) regimen of 110mg dabigatran etexilate b.i.d. plus clopidogrel or ticagrelor (110mg dabigatran etexilate (DE) DAT) and 150mg dabigatran etexilate…
- Trial name
- NCT02164864
- Testing
- Dabigatran Etexilate 110mg, Warfarin 3mg, Aspirin
- Where
- 421 sites in United States, Argentina and 39 more
- Volunteers
- 2,725 people
- Sponsor
- Boehringer Ingelheim
Acute Coronary Syndrome, STEMI
Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg in Elderly Patients With ACS
Elderly individuals are increasingly represented among patients with acute coronary syndrome (ACS). Dual antiplatelet therapy (DAPT) with aspirin and an oral P2Y12 receptor inhibitor has an established role in the prevention of…
- Conditions
- Acute Coronary Syndrome, STEMI, NSTEMI, Coronary Artery Disease
- Trial name
- PlinytheElder (NCT04739384)
- Testing
- Ticagrelor 90mg, Ticagrelor 60 mg
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Federico II University
Coronary Artery Disease, Myocardial Infarction
Bedside Testing of CYP2C19 Gene for Treatment of Patients With PCI With Antiplatelet Therapy
Clopidogrel is crucial as antiplatelet treatment in patients undergoing percutaneous coronary intervention (PCI) with stent implantation and during one year after PCI, to prevent atherothrombotic complications.
- Conditions
- Coronary Artery Disease, Myocardial Infarction, Heart Disease, Vascular Disease
- Trial name
- NCT01823185
- Testing
- clopidogrel, Ticagrelor or prasugrel
- Where
- 4 sites in Saudi Arabia
- Volunteers
- 1,500 people
- Sponsor
- Imam Abdulrahman Bin Faisal University
Acute Coronary Syndrome
Evaluation of Ticagrelor Anti Platelet and Pleiotropic Effects in Patients Undergoing Percutaneous Coronary Intervention for an Acute Coronary Syndrome
Ticagrelor is a new P2Y12 ADP receptor antagonist. This drug demonstrated a faster onset of action and a higher potency compared to clopidogrel standard regimen.
- Trial name
- NCT01626534
- Testing
- Clopidogrel, trigagrelor
- Where
- France
- Volunteers
- 125 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Platelet Reactivity
Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable CAD.
Ticagrelor has been demonstrated to provide a more rapid and more powerful inhibition of platelet aggregation compared with clopidogrel in coronary artery disease (CAD) patients.
- Trial name
- NCT03679091
- Testing
- low-dose ticagrelor, Clopidogrel
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Coronary Microvascular Disease, Ticagrelor
Effect of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients With Acute Myocardial Infarction
Of the patients diagnosed with ST-segment elevation myocardial infarction (STEMI) who underwent reperfusion therapy and have thrombolysis in myocardial infarction (TIMI) 3 flow, about 40% have flow alterations in the coronary…
- Conditions
- Coronary Microvascular Disease, Ticagrelor, Thrombolysis, Microbubble Contrasted Echocardiography
- Trial name
- NCT03104062
- Testing
- Microbubble Contrasted Echocardiography, Platelet Aggregability, Laboratory
- Where
- Brazil
- Volunteers
- 48 people
- Sponsor
- University of Sao Paulo General Hospital